The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
Earlier in December, telehealth company Ro announced a partnership with Eli Lilly to offer a half-price version of Zepbound, Lilly's brand-name tirzepatide product. The cheaper option is sold in ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version ... years of being in shortage, tirzepatide — the active ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...
The Healthy on MSN13d
FDA Announcement: The First Generic GLP-1 Shot Has Just Been ApprovedThis may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback